Latest news with #RobertWay
Newsweek
4 days ago
- Newsweek
Spouse Turns To Unlikely Source of Comfort After Wife of 28 Years Dies: 'Somehow, It Helps'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. When a "broken" man lost his wife of 28 years, he found solace in an unexpected source: an AI chatbot. The grieving man opened up on Reddit to explain that for 14 of their years together, his wife had used a wheelchair and required constant care. The original poster (OP) dancopPL described how his life once revolved around her, five days after she died. "Everything, my job, our routines, the way I planned each day and night, was built around her needs," the OP wrote. "And she was the most intelligent person I've ever known." Stock image: Apps including ChatGPT on a phone screen. Stock image: Apps including ChatGPT on a phone screen. Photo by Robert Way / Getty Images The OP added that her death came suddenly and unrelated to her long-term condition. "It came without warning," he told Redditors. "I held her in my arms as her heart stopped. I performed CPR until the ambulance arrived, and then we fought with two teams of medics for nearly an hour. But she was already gone the moment she closed her eyes in my arms." 'Somehow it helps' According to the OP, his grief has been "overwhelming." However, the man said he has been familiar with and using artificial intelligence (AI) tools for a long time. Now, they are becoming an emotional outlet and, to his surprise, he said it's helping. "Grieving. Broken. Awake at 4 a.m. with tears in my eyes and talking to an AI. And somehow, it helps," he wrote. "It doesn't fix the pain. But it absorbs it. It listens when no one else is awake. It remembers. It responds with words that don't sound empty." He added: "I know it's not real. I'm not pretending it's a friend or a therapist. But when the nights are long and your world has shattered, just having something to talk to without shame or fear, can be the difference between falling apart and holding on." The man acknowledged that ChatGPT won't be able to fix the pain of losing a spouse. "I probably will be [grieving] for the rest of my life," he wrote. "But this unexpected lifeline I once saw only as a novelty or a work aid, is giving me a strange sort of comfort... even if it's a chatbot." Newsweek reached out to dancopPL requesting further comment. 'Grief doesn't follow office hours' David Kessler is an author and founder of whose work studying grief and the needs of the dying drew praise from Mother Theresa. In an email, Kessler told Newsweek that he has been asked if AI will replace him in grief work for more than a decade. "At first, I was annoyed—grief is deeply human and nothing replaces real connection," Kessler said, "But I knew AI was coming and I hoped it would be done well." Kessler said chatbots were too flattering, or too clinical at first, so he created one himself. "It's not meant to replace human connection, but to gently offer comfort, clarity and guidance when someone needs it," he said. "Grief doesn't follow office hours. [...] "When used thoughtfully, my hope is that my AI can provide comfort, normalize emotions and offer a soft landing when someone doesn't know where to turn. They're not a replacement for therapy or community, but they can be part of a larger circle of support." 'Sacred gestures' Kessler added that it's important to remember that AI cannot grieve or love and it can't offer professional or emotional support in the form of a real conversation. "The family showing up with dinner, a friend who just sits and listens with love in their eyes, someone who remembers your loved one's birthday, the phone call out of the blue, these are sacred gestures," he said. "They say, 'You matter. Your loss matters.' "AI can offer information. People offer love."
Yahoo
29-05-2025
- Automotive
- Yahoo
Li Auto Q1 Vehicle Deliveries Jump 15%, Continues High Cash Burn
Li Auto Inc. (NASDAQ:LI) stock declined on Thursday after it reported fiscal first-quarter 2025 results. The company reported quarterly revenue growth of 1.1% year-on-year to 25.9 billion Chinese yuan ($3.6 billion), beating the analyst consensus of 25.3 billion Chinese yuan ($3.5 billion). Its adjusted net earnings per ADS were 0.96 Chinese yuan (13 cents), beating the analyst consensus estimate of 0.89 Chinese yuan (12 cents). Vehicle sales increased 1.8% to $3.4 billion due to increased vehicle deliveries partially offset by the lower average selling price, mainly due to different product mixes. Total vehicle deliveries were 92,864 units in the quarter, a 15.5% Y/Y increase. Also Read: The vehicle margin climbed 50 bps to 19.8%, and the gross margin remained flattish at 20.5%, backed by cost management and growing economies of scale. Adjusted income from operations was $88.1 million, up by 537.2% Y/Y. Adjusted net income decreased 20.5% Y/Y to $139.8 million. Li Auto held cash and equivalents of $15.3 billion as of March 31, 2025, and used $234.4 million in operating cash flow for the quarter, down by 49.1% Y/Y. The free cash flow used was $348.7 million, down by 49.9% Y/Y. As of March 31, 2025, the company had 500 retail stores covering 150 cities, 502 servicing centers, Li Auto-authorized body and paint shops operating in 225 cities, and 2,045 supercharging stations with 11,038 charging stalls. For the second quarter of 2025, Li Auto expects revenue of 32.5 billion Chinese yuan to 33.8 billion Chinese yuan ($4.5 billion to $4.7 billion), representing an increase of 2.5%-6.7% Y/Y compared to the analyst consensus estimate of 32.94 billion Chinese yuan ($4.54 billion). Li Auto expects vehicle deliveries of 123,000-128,000 for the second quarter of 2025, representing an increase of 13.3%-17.9% Y/Y. The company attributed the fiscal first-quarter 2025 results to effective cost management and growing economies of scale despite the typical seasonal slowdown in auto sales and product iterations. The company affirmed its ability to navigate market dynamics and achieve profitability with plans for continued growth through innovation and efficiency. Li Auto is confident in its strategic initiatives, including the upcoming launch of its first battery-electric SUV, the Li i8, in July. Price Action: LI stock is down by 4.30% to $26.70 premarket at last check Thursday. Read Next:Photo by Robert Way via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Li Auto Q1 Vehicle Deliveries Jump 15%, Continues High Cash Burn originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Automotive
- Yahoo
China's XPeng EV Deliveries Jump 330%, CEO Cites Margin Improvement For 7 Consecutive Quarters
Chinese EV maker XPeng Inc. (NYSE:XPEV) stock gained on Wednesday after reporting its fiscal first-quarter results. The company reported quarterly sales growth of 141.5% year-on-year to 15.81 billion Chinese yuan ($2.18 billion), topping the analyst consensus estimate of 16.02 billion Chinese yuan. The Tesla Inc (NASDAQ:TSLA) rival's quarterly vehicle deliveries increased 330.8% Y/Y to 94, physical sales network had 690 stores, covering 223 cities as of March 31, 2025. XPeng's self-operated charging station network reached 2,115 stations as of March 31, 2025. Revenues from vehicle sales increased 159.2% year over year to 14.37 billion Chinese yuan ($1.98 billion) due to higher deliveries. Gross margin was 15.6% versus 12.9% a year ago. Vehicle margin was 10.5% versus 5.5% a year ago, primarily attributable to the cost reduction and economies of scale driven by the increase in sales volume. The EV maker said its gross margin has increased for seven consecutive quarters. Operating loss for the quarter was 1.04 billion Chinese yuan ($0.14 billion). Adjusted net loss per ADS was 0.45 Chinese yuan. In USD terms, the adjusted EPADS was a loss of 6 cents. The company held $6.24 billion in cash and equivalents as of March 31, 2025. Chair and CEO Xiaopeng said, 'Despite seasonality for auto sales, our quarterly deliveries hit a new historical high, making us the top-selling automaker among emerging EV companies. Positive market feedback strengthened our confidence in our three-year product cycle. We remain committed to our steadfast long-term growth strategy and continue to launch more blockbuster products.' Outlook: XPENG projects second-quarter vehicle deliveries between 102,000 and 108,000 units, reflecting a surge of 237.7%-257.5% Y/Y. The company anticipates revenue of 17.5 billion Chinese yuan to 18.7 billion Chinese yuan, versus the analyst consensus estimate of 16.85 billion Chinese yuan. Price Action: XPEV shares are up 6.65% at $20.99 premarket at the last check on Wednesday. Read Next:Photo by Robert Way via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article China's XPeng EV Deliveries Jump 330%, CEO Cites Margin Improvement For 7 Consecutive Quarters originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Newsweek
14-05-2025
- Entertainment
- Newsweek
When Did HBO Change to HBO Max? What We Know as Service Renamed Again
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Warner Bros. Discovery is reviving the HBO Max name after abandoning it over a year ago in favor of the shorter "Max" brand, officials announced Wednesday. The media giant announced that the change will take effect in the U.S. this summer, reflecting a course prompted by "changing consumer needs," the company said in a press release. The move underscores how critical HBO's name recognition remains, even as the company continues to build a broader streaming portfolio under one platform. File photo of the Disney+, HBO Max and Hulu app icons on a phone screen. File photo of the Disney+, HBO Max and Hulu app icons on a phone screen. Robert Way/iStock/Getty Images Warner Bros. Rebrand: When Will HBO Change Back to HBO Max? The updated HBO Max brand will officially return this summer, according to Warner Bros. Discovery. "This evolution has also been influenced by changing consumer needs, and the fact that no consumer today is saying they want more content, but most consumers are saying they want better content," the company's press release said. At the time, executives hoped the simplified name would reflect the streaming service's growing catalog of content, which includes everything from scripted dramas to reality TV. Casey Bloys, Chairman and CEO of HBO and Max Content, said HBO Max "far better represents our current consumer proposition" and reiterates the brand's promise to deliver unique and "worth paying for" content. Returning HBO to HBO Max, which has added over 22 million subscribers over the past year, will further drive the service forward and amplify the content subscribers can expect. JB Perrette, CEO and president of Global Streaming and Games at Warner Bros. Discovery, said: "We will continue to focus on what makes us unique – not everything for everyone in a household, but something distinct and great for adults and families. It's really not subjective, not even controversial – our programming just hits different." When Did HBO Change to HBO Max? HBO Max launched on May 27, 2020, consolidating content from HBO, Warner Bros., and additional WarnerMedia-owned properties. The HBO Go service was discontinued in the U.S. later that year, providing a unified streaming destination for U.S. subscribers. In 2023, following the merger of WarnerMedia and Discovery, Inc., Warner Bros. Discovery dropped the "HBO" branding and launched the service simply as Max. The rebrand aimed to better highlight the expanded content lineup, which now included Discovery Channel, HGTV, and Food Network content, also available through Discovery+. Why Is the Name Changing Again? The company cited existing success and changing consumer needs as the reasons for the name swap. David Zaslav, president and CEO of Warner Bros. Discovery, said bringing back HBO will "accelerate growth in the global streaming service." What Shows Are on HBO? HBO's original programming continues to be central to the platform's identity, with series like Succession, The White Lotus, Euphoria, and House of the Dragon drawing critical acclaim and strong viewer engagement. Classic hits like The Sopranos, The Wire, and Game of Thrones remain on the service. In addition to scripted dramas and comedies, HBO offers a slate of documentaries, late-night shows like Real Time with Bill Maher, and weekly talk programming such as Last Week Tonight with John Oliver. The broader Max platform also includes content from Discovery-owned networks, such as Fixer Upper from HGTV and Deadliest Catch from the Discovery Channel. The shift back to HBO Max is widely seen as a correction that will help rebuild clarity and reinforce the platform's identity in a crowded streaming market. What Happens Next Warner Bros. Discovery plans to relaunch the HBO Max name in the U.S. during summer 2025. The company has not announced any changes to pricing or subscription tiers.
Yahoo
31-03-2025
- Business
- Yahoo
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) for adult patients with muscle-invasive bladder cancer (MIBC). The FDA approval was based on results from the NIAGARA Phase 3 trial. In a planned interim analysis, the Imfinzi-based perioperative regimen demonstrated a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus the comparator arm. Also Read: The estimated median event-free survival (EFS) has not yet been reached for the Imfinzi arm versus 46.1 months for the comparator arm. An estimated 67.8% of patients treated with the regimen were event-free at two years compared to 59.8% in the comparator arm. Results from the key secondary endpoint of overall survival (OS) showed that the Imfinzi-based perioperative regimen reduced the risk of death by 25% versus neoadjuvant chemotherapy with radical cystectomy. Median survival was not yet reached for either arm. An estimated 82.2% of patients treated with the regimen were alive at two years compared to 75.2% in the comparator arm. Concurrently, AstraZeneca's Calquence (acalabrutinib) in combination with bendamustine and rituximab was recommended for approval in the European Union for adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous hematopoietic stem cell transplantation. The positive opinion was based on the ECHO Phase 3 trial results. Calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy. Median PFS was 66.4 months for patients treated with the Calquence combination versus 49.6 with chemoimmunotherapy alone. Price Action: AZN stock is down 0.86% at $73.16 at the last check Monday. Read Next:Image by Robert Way via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ASTRAZENECA (AZN): Free Stock Analysis Report This article FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
